**CLAIMS**

1. *A* compound of structural formula (I), as an activators of Histone acetyltransferases, ***containing ring A derived from substituted benzoic acid moiety and ring B is substituted anilide*** wherein:

**R1** is H, Methyl, Ethyl, n-Propyl, Isopropyl, n-butyl, t-butyl, $C_8H_{18}$,$C_{15}H_{26}$ , $C_{15}H_{28}$, $C_{15}H_{30}$, $C_{15}H_{32}$;

**R2** is H, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl and *t*-butyl;

**R3** is H, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl and *t*-butyl, $CF_3$, $CCl_3$, $CI_3$, F, Cl, I, $NO_2$, CN;

**R4** is H, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl and *t*-butyl, $CF_3$, $CCl_3$, $CI_3$, F, Cl, I, $NO_2$, CN;

**R5** is H, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl and *t*-butyl, $CF_3$, $CCl_3$, $CI_3$, F, Cl, I, $NO_2$, ;

**R6** is H, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl and *t*-butyl, $CF_3$, $CCl_3$, $CI_3$, F, Cl, I, $NO_2$, CN; and

**R7** is H, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl and *t*-butyl, $CF_3$, $CCl_3$, $CI_3$, F, Cl, I, $NO_2$, CN.

2. A compound of structural formula (II) ***for ring A of formula (I)*** the accompanying drawings for inhibitor of Histone acetyltransferases, wherein:

**R1** is H, $CH_3$, Hydroxyl, Carboxylic, O-Methoxy, O-Ethoxy, n-Propoxy , O-Isopropoxy, n-butoxy, t-butoxy, $C_8H_{18}$ ,$C_{15}H_{26}$ , $C_{15}H_{28}$, $C_{15}H_{30}$, $C_{15}H_{32}$;

**R2** is H, $CH_3$, Hydroxyl, Carboxylic, O-Methoxy, O-Ethoxy, n-Propoxy , O-Isopropoxy, n-butoxy, t-butoxy, $C_8H_{18}$ ,$C_{15}H_{26}$ , $C_{15}H_{28}$, $C_{15}H_{30}$, $C_{15}H_{32}$;

**R3** is H, $CH_3$, Hydroxyl, Carboxylic, O-Methoxy, O-Ethoxy, n-Propoxy , O-Isopropoxy, n-butoxy, t-butoxy, $C_8H_{18}$ ,$C_{15}H_{26}$ , $C_{15}H_{28}$, $C_{15}H_{30}$, $C_{15}H_{32}$;

**R4** is H, $CH_3$, Hydroxyl, Carboxylic, O-Methoxy, O-Ethoxy, n-Propoxy , O-Isopropoxy, n-butoxy, t-butoxy, $C_8H_{18}$ ,$C_{15}H_{26}$ , $C_{15}H_{28}$, $C_{15}H_{30}$, $C_{15}H_{32}$;

**R5** is H, $CH_3$, Hydroxyl, Carboxylic, O-Methoxy, O-Ethoxy, n-Propoxy , O-Isopropoxy, n-butoxy, t-butoxy, $C_8H_{18}$ ,$C_{15}H_{26}$ , $C_{15}H_{28}$, $C_{15}H_{30}$, $C_{15}H_{32}$;

**R6** is H, $CH_3$, Hydroxyl, Carboxylic, O-Methoxy, O-Ethoxy, n-Propoxy , O-Isopropoxy, n-butoxy, t-butoxy, $C_8H_{18}$ ,$C_{15}H_{26}$ , $C_{15}H_{28}$, $C_{15}H_{30}$, $C_{15}H_{32}$.

3. A process of preparing compounds as described in formula1 or formula II by known methods.

4. A method of treating a patient suffering from diseases due defects in gene regulation predominantly or at risk of, cancer, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I) to activate histone acetyltransferases or formula (II) to inhibit histone acetyltransferase or a pharmaceutically acceptable salt or solvate of these compounds.